Pharma: Page 4
-
Chip Somodevilla via Getty Images
Turning the page: Novo’s CEO transition reflects Big Pharma’s era of change
Turnover of the top execs at pharma giants like J&J, AbbVie and Merck in the last few years illustrates the seismic industry shifts that often accompany leadership changes.
By Michael Gibney • May 22, 2025 -
Permission granted by Zealand Pharma
Q&A // First 90 DaysLilly’s former small molecule head makes the leap to a rising biotech in obesity
Utpal Singh joined the peptide-focused biotech Zealand Pharma last month after it notched a massive obesity deal with Roche.
By Amy Baxter • May 21, 2025 -
Explore the Trendline➔
Stock via Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
Justin Sullivan via Getty Images
Regeneron wins bid to buy 23andMe out of bankruptcy
The biotech, which has for years invested in genetics research, plans to acquire "substantially all" of testing firm 23andMe's assets for $256 million.
By Ned Pagliarulo • May 20, 2025 -
Stock via Getty Images
The placebo effect: How a new FDA rule could pile more strain onto vaccine developers
The proposed plan would require placebo testing for all new vaccines and could mean additional costs and time for R&D.
By Alexandra Pecci • May 20, 2025 -
Andrew Harnik via Getty Images
With the third round of Medicare price negotiations on the way, here’s how the policy is shifting
HHS issued guidance for the third cycle, teeing up another 15 drugs to be selected by early next year.
By Amy Baxter • May 19, 2025 -
Stock via Getty Images
Tracking a moving target: Drugmakers brace for a looming tariff impact
With policies in flux, companies seek to be proactive and understand their supply chain.
By Kelly Bilodeau • May 19, 2025 -
Philip Pacheco via Getty Images
A startup with Theranos ties has another blood test in the works. This time, competition is waiting.
A stealth startup built by the partner of disgraced Theranos founder Elizabeth Holmes is taking a shot at a new blood test — an area where other companies are already making strides.
By Meagan Parrish • May 16, 2025 -
FatCamera via Getty Images
Women’s health faces growing headwinds, despite jump in venture investment
While venture funding is rising, federal policy upheaval may affect women’s health research more acutely than other fields, one biotech CEO said.
By Delilah Alvarado • May 14, 2025 -
Andrew Harnik/ via Getty Images
Trump’s ‘most favored nation’ policy is back. Here’s why it failed the first time.
The controversial plan aims to lower drug prices and will surely trigger another fight with pharma.
By Amy Baxter • May 14, 2025 -
Andrew Harnik via Getty Images
FDA’s future in MAHA hands: How leadership is changing the agency’s trajectory
Who’s in, who’s out and which key positions are still left to be filled in an agency upended.
By Alexandra Pecci • May 13, 2025 -
iStock via Getty Images
With the breakneck speed of cancer breakthroughs, oncologists feel left behind. Can Big Pharma chime in?
Community oncologists do their best to keep up with new treatments, but with the pace of cancer approvals, drugmakers need to team up with doctors on the front line.
By Michael Gibney • May 13, 2025 -
Sedat Suna via Getty Images
Lupus R&D has come a long way, and the next breakthroughs could come from cell therapy
But the therapies will need to prove their worth in the clinic over the next few years.
By Kelly Bilodeau • May 12, 2025 -
Stock via Getty Images
AI is already delivering pharma value — and not just in drug discovery
While AI-generated drugs grab headlines, the technology is making more of an impact doing less “glamorous” tasks.
By Meagan Parrish • May 12, 2025 -
Michael M. Santiago via Getty Images
RFK Jr.’s autism fixation hearkens back to his stance on vaccines
The head of HHS is seeking the “root causes” of autism spectrum disorder through a large government research project.
By Amy Baxter • May 9, 2025 -
Jacob Bell/PharmaVoice
Alnylam keeps pushing the rare disease paradigm as RNAi promises even wider indications
With another rare disease approval under its belt, Alnylam is still revving up the R&D engines for new indications.
By Michael Gibney • May 8, 2025 -
Stock via Getty Images
Prasad’s FDA appointment pressures cell and gene therapy stocks
A vocal opponent of his predecessor Peter Marks, Dr. Vinay Prasad will now lead the office tasked with reviewing some genetic medicines, adding more uncertainty to an already struggling field of research.
By Ben Fidler • May 7, 2025 -
Stock via Getty Images
With TV ads under threat, here’s how pharma can leverage social media
RFK Jr.’s plan to ban TV advertising may shift more marketing attention to online platforms.
By Amy Baxter • May 7, 2025 -
Kevin Dietsch via Getty Images
On tariffs and pricing, Big Pharma CEOs are waiting out the storm while planning for the worst
Chief executives at the largest drugmakers in the world are confident tariffs and pricing measures won’t be a major problem. But they’re still poised for change.
By Michael Gibney • May 6, 2025 -
Stock via Getty Images
After an up and down year, pharma’s R&D landscape is shifting again
While clinical trial funding was up, deal-making was down, and new uncertainties are coming into the picture.
By Kelly Bilodeau • May 5, 2025 -
Spencer Platt via Getty Images
With compounders out of the way, Lilly and Novo go after each other
The two obesity leaders are pulling on all levers to stay on top of the market.
By Amy Baxter • May 5, 2025 -
Stock via Getty Images
Is pharma ready to let go of animal testing?
Regulators have signaled their willingness to embrace alternative tests and guide the industry in new directions.
By Meagan Parrish • May 2, 2025 -
Courtesy of Johnson & Johnson
J&J scores FDA OK for immune drug touted as future blockbuster
The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in annual sales at its peak.
By Ned Pagliarulo • May 1, 2025 -
Stock via Getty Images
Q&ACan real-world evidence bear some of the burden left by NIH cuts? This CEO sees an opportunity.
Turmoil at the NIH has led to handwringing among researchers and drugmakers who rely on public funding.
By Michael Gibney • May 1, 2025 -
Andrew Harnik via Getty Images
Is the FDA headed for a major reorganization?
A leaked document revealed details about changes that could impact how the agency operates, but recent comments from FDA Commissioner Dr. Marty Makary have muddied the picture.
By Amy Baxter • April 30, 2025 -
Sarah Silbiger via Getty Images
FDA’s job cuts paint mixed picture for drugmakers’ R&D plans
After a 20% cut to the FDA’s workforce, biotechs and pharmas are bracing for delays. But the impacts won’t be consistent.
By Amy Baxter • April 28, 2025
Previous
